Back to library
HealingSubcutaneous
Pentadeca Arginate
Also known as: PDA · PDA-1 · BPC-157 Arginate
Salt form of the BPC-157 pentadecapeptide complexed with arginate. Marketed as a more stable, longer-shelf-life analog of BPC-157 with the same downstream effects — angiogenesis, VEGF upregulation, and accelerated soft-tissue repair. Direct comparative human data is limited.
At a glance
- Half-life
- 4 hours
- Common route
- Subcutaneous
- Typical dose range
- 250–1,000mcg
- Stability (reconstituted)
- 60days refrigerated
Best timing
1–2x daily. Subq injection near the injury site preferred. Reconstituted stability is the main practical advantage over BPC-157 acetate.
Contraindications
- Active cancer (theoretical angiogenic concern)
- Pregnancy
- Known hypersensitivity
Watch symptoms
- Injection site irritation
- Mild fatigue early in protocol
- GI changes if dosed orally
- Limited independent human safety data — most evidence extrapolated from BPC-157 research
Citations